Mdma-at-bn

Phase 1

IIcahn School of Medicine at Mount Sinai

Mdma-at-bn is one of 8 therapeutic programs targeting Bulimia Nervosa. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Bulimia NervosaRecruiting

Bulimia NervosaPhase 1

Recruiting

Competition

Competitive Landscape

8 competitors in Bulimia Nervosa

#DrugCompanyPhaseTrials

Acetadote

AArbor Pharmaceuticals, Inc.

Prometrium

Lioresal

1 4

Namenda

AbbVie

Preclinical

1 5

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

3 6

Benadryl

PParkedale

Preclinical

1 7

MDMA-AT

HHerzog Hospital

Phase 1

1 8

Mdma-at-bn

IIcahn School of Medicine at Mount Sinai

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Bulimia Nervosa

NCT07542145

Clinical

Trials by Indication[1]

Bulimia Nervosa1 trial

MDMA Assisted Therapy for Bulimia Nervosa: A Treatment Development Protocol

Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 1·NCT07542145·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mdma-at-bn. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Mdma-at-bn. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Icahn School of Medicine at Mount Sinai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: IIcahn School of Medicine at Mount Sinai

Mdma-at-bn

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Bulimia Nervosa1 trial

References

Drug Info

Quick Facts

Related News